Report Details:
15 Companies Covered
128 Pages
Global Cardiopulmonary Exercise Testing Market Highlights
The Cardiopulmonary Exercise Testing Market Size was estimated at 0.96 USD Billion in 2024. The Cardiopulmonary Exercise Testing industry is projected to grow from USD 1.03 Billion in 2025 to USD 2.091 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.33% during the forecast period 2025 - 2035.
The growth of the global Cardiopulmonary Exercise Testing market is attributed to the increase in the prevalence of cardiovascular diseases and a rising geriatric population. For instance, according to the UN, by 2050, 1 in 6 people around the globe will be over the age of 65, up from 1 in 11 in 2023.
According to the Rural Health Information Hub, in the US, the number of older adults aged 65 and older is expected to grow to almost 90 million by 2050. In addition, by 2030, 1 in 5 Americans is projected to be 65 years old or over. However, the lack of skilled and experienced professionals are anticipated to hamper the market growth.
MRFR recognizes the following companies as the key players in the global Cardiopulmonary Exercise Testing market— Vyaire Medical, Inc (US), MGC Diagnostics Corporation (US), COSMED srl (Italy), CORTEX Biophysik GmbH (Germany), Oxigraf, Inc (US), Koninklijke Philips NV (Netherlands), Hill-Rom Holdings, Inc (US), MEDEV Medical Devices Corporation (Saudi Arabia), and Geratherm Medical AG (Germany), and others.
Segment Analysis
The global Cardiopulmonary Exercise Testing market has been segmented based on product, and end user.
On the basis of product, the global Cardiopulmonary Exercise Testing market has been segmented into CPET metabolic carts and software.
The Cardiopulmonary Exercise Testing market, based on end user, is segmented into hospitals & clinics, diagnostic centers, ambulatory centers, and others. The hospitals & diagnostic centers segment accounted for the largest market. One of the major factors contributing to the growth of hospitals & diagnostic centers is that the companies are differentiating their product pipeline to address the challenges while diagnosing. Companies such as Vyaire Medical, Inc (US), MGC Diagnostics Corporation (US) are among the leading firms that have diversified cardiopulmonary exercise testing product portfolios to cater to the medical needs of the consumers.
Regional Analysis
The global cardiopulmonary exercise testing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. The North America further includes US and Canada. The Europe includes countries namely Germany, France, UK, Italy, Spain, and Rest of Europe. The Cardiopulmonary Exercise Testing market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.
North America dominated market in 2022 due to factors such as the the presence of active industry players in the region and the availability of the products propelling the market's growth in North America . According to the American Heart Association, coronary heart disease was one of the leading causes of death in the US in 2020 and account for 41.2% of deaths, followed by stroke (17.3%), other cardiovascular diseases (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery diseases (2.6%).
The Europe region shows significant growth during the forecast period. This is due to the rising prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and metabolic conditions that is driving the demand for CPET in Europe. CPET provides valuable diagnostic and prognostic information for these conditions, aiding in personalized treatment and management strategies. As per the European Survey of Cardiovascular Disease by Daiichi Sankyo Europe GmbH (Germany), there were approximately 60 million people living with CVD, and 13 million new cases were diagnosed in 2020.
Asia Pacific region is fastest growing region in market in 2022 owing to factors such as the owing to high applications of CPET in the geriatric population as aging populations are more prone to CVDs. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022.
The rest of the world Cardiopulmonary Exercise Testing market is segmented into major regions, namely the Middle East, Africa, and Latin America. The rest of the world region is comprised of the Middle East, Latin America, and Africa. The increasing prevalence of CVDs is an imperative factor to consider for the region’s growth. As per the World Heart Federation, more than 1 million deaths occurred due to CVD in sub-Saharan Africa in 2019. Furthermore, 1.4 million people die each year in the Middle East and North Africa (MENA) region.
Furthermore, rising cases of lung cancer which CPET utilizes in preoperative and postoperative settings for measuring oxygen levels, are another driving factor for market growth. As per GLOBOCAN 2020, the incidence of lung cancer was 45,988 and mortality was 41,171 in both sexes in Africa.
Key Findings of the Study
- North America remains the largest market for cardiopulmonary exercise testing, reflecting a robust healthcare infrastructure and high demand for advanced diagnostic tools.
- The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and a growing population seeking preventive health solutions.
- CPET metabolic carts dominate the market, while software solutions are rapidly gaining traction as the fastest-growing segment due to the integration of telehealth technologies.
- Key market drivers include the rising incidence of cardiovascular diseases and the growing awareness of exercise physiology, which are propelling demand across hospitals and clinics.
